To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).
Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback